Johnson & Johnson has come out fighting after Pfizer announced yesterday that it is ready to launch a biosimilar competitor to its blockbuster Remicade. J&J said it had a “biosimilar ...

The global remicade biosimilar market is projected to expand significantly between 2025 and 2035, with a market size growing from USD 2.32 billion in 2025 to USD 4.01 billion in 2035, at a robust ...

The Remicade Biosimilar market Is Poised for Robust Growth, Expanding from USD 2.32 Billion in 2025 To USD 4.10 Billion by 2035 At A CAGR of 5.4%. NEWARK, DE, UNITED STATES, January 30 ...

Today, a patient might be prescribed Remicade, which, when infused can help treat rheumatoid arthritis. If a patient requests a biosimilar such as Inflectra, which is 17 percent less expensive on ...

The Department of Veterans Affairs (VA) saved $67 million in 2023 through its strong adoption of biosimilars to curb the high ...

Caruso said the period for the Remicade biosimilar ends early in October and there can be no launch before that. He added: “We will be vigorously defending our patent. Whether or not a ...

The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.

Number 1: In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ...

At least, not exactly. The drug is already facing biosimilar competition in the US, which would challenge Remicade's share of the market. By some estimates, biosimilars could save the US $250 ...